NASDAQ:MCRB Seres Therapeutics Q4 2025 Earnings Results & Report $1.44 +0.03 (+2.13%) Closing price 04:00 PM EasternExtended Trading$1.43 -0.01 (-0.62%) As of 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Seres Therapeutics beat analyst earnings expectations in its Q4 2025 results, released March 12, 2026. The company reported EPS of -$1.89 versus the -$2.39 consensus estimate, while revenue was $438 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 12, 2026TimeBefore Market OpensConference Call9:00 AM ET Seres Therapeutics EPS ResultsActual EPS-$1.89Consensus EPS -$2.39Beat/MissBeat by +$0.50One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersSeres Therapeutics Revenue ResultsActual Revenue$438 thousandExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Seres Therapeutics Q4 2025 Earnings FAQ Did Seres Therapeutics beat earnings estimates for Q4 2025? Seres Therapeutics (NASDAQ:MCRB) reported earnings of -$1.89 per share for Q4 2025, beating the consensus estimate of -$2.39. The report was announced on Thursday, March 12, 2026. What was Seres Therapeutics' revenue for Q4 2025? Seres Therapeutics reported revenue of $438 thousand for Q4 2025. Seres Therapeutics Earnings HeadlinesAnalysts Offer Insights on Healthcare Companies: Pacific Biosciences (PACB), Seres Therapeutics (MCRB) and Relay Therapeutics (RLAY)November 8, 2026 | theglobeandmail.comEquities Analysts Set Expectations for MCRB FY2026 EarningsNovember 8, 2026 | americanbankingnews.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 18 at 1:00 AM | Profits Run (Ad)Seres Therapeutics (NASDAQ:MCRB) Stock Moved Down to Strong Sell by Wall Street ZenNovember 7, 2026 | americanbankingnews.comSeres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related ...November 4, 2026 | markets.businessinsider.comSeres Therapeutics: Q3 earnings snapshotNovember 4, 2026 | msn.comSee More Seres Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Seres Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Seres Therapeutics and other key companies, straight to your email. Email Address About Seres TherapeuticsSeres Therapeutics (NASDAQ:MCRB) is a biotechnology company based in Cambridge, Massachusetts, focused on developing microbiome-based medicines. Its approach uses live biotherapeutic products designed to influence the gut microbiome and address conditions including infections and complications associated with impaired immune function.The company developed VOWST, an oral microbiota-based therapy approved in the United States to prevent recurrent Clostridioides difficile infection in adults after antibacterial treatment. Seres developed the product in collaboration with Nestlé Health Science, which acquired rights to VOWST.Seres has also advanced investigational candidates such as SER-155, an oral live biotherapeutic being studied for potential use in people at risk of infections related to immune suppression. The company’s research builds on its work in microbiome science and therapeutic development.View Seres Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes ShapeGeneral Motors Faces a Cost Squeeze as Factory Automation Takes Center StageNVIDIA's Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?5 Consumer Discretionary Plays Showing Strength During the Tech Sell-OffAMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?Viking’s Low-Water Miss Looks Like a Buy-the-Dip OpportunityDisney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout Upcoming Earnings NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.